Eli Lilly and Purdue Expand Partnership With $250 Million Investment
US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...
CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...
CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG
Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...
Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development
China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...
InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...
AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small...
IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma
China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...
Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...
RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...
NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million
Shenzhen-based XtalPi Holdings Limited (HKG: 2228) announced plans to acquire a 90% stake in Re...
Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...
Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...
J&J’s Tremfya Approved for Ulcerative Colitis in China
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...
China’s CDE Reveals 93rd Batch of Reference Preparations for GQCE
China’s Center for Drug Evaluation (CDE) has released the 93rd batch of reference preparations for...
NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management
The National Health Commission (NHC) this week released the “Guidelines for the Construction and Management...
Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April...
Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report...
Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...